Siemens Healthineers Investors Await Answers on Two Fronts

Siemens Healthineers cuts 2026 EPS forecast amid U.S. tariffs and China headwinds. Investors await spin-off details as new CTO aims to boost AI for diagnostics.

Investors in Siemens Healthineers are facing a dual challenge: navigating significant near-term financial headwinds while awaiting clarity on a major strategic shift. The company is under pressure to deliver details on its planned separation from parent Siemens AG, having missed a self-imposed deadline for providing a roadmap in early April. Management now faces intense questioning at the HSBC Global Investment Summit in Hong Kong.

The operational landscape remains difficult. For the full 2026 fiscal year, management has already revised its adjusted earnings per share forecast downward to a range of EUR 2.20 to EUR 2.40. This cut reflects substantial external pressures, including U.S. tariff impacts expected to reduce adjusted EBIT by approximately EUR 400 million and negative currency effects costing an additional EUR 200 to 250 million.

These challenges were evident in first-quarter results. While group revenue grew by 3.8%, adjusted earnings per share fell by 3% to EUR 0.49. The diagnostics division was a primary weak spot, with revenue declining 3% year-over-year. A state-led anti-corruption campaign in China, coupled with stricter centralized procurement processes, is significantly dampening business in this key market.

Amid these hurdles, the company is pushing forward with a technological refresh. Martin Stumpe, a former developer for Google and NASA, is set to take over as Chief Technology Officer on June 1, 2026. He succeeds Peter Schardt after a seven-year tenure. Stumpe, joining from Danaher, is tasked with massively expanding the firm's AI capabilities, with a strategic focus on "Patient Twinning" technology for advanced diagnostics. His first major presentation is expected at the DMEA healthcare IT conference in Berlin, starting April 21.

The market's reaction to this mix of strategic promise and operational strain has been cautious. The share price currently trades around EUR 38.40, marking a decline of roughly 13% since the start of the year. It now sits nearly 23% below its 52-week high of almost EUR 50. Analyst sentiment is mixed; Goldman Sachs recently lowered its price target from EUR 52 to EUR 45, citing persistent risks in the diagnostics business.

The looming share distribution by Siemens AG adds another layer of uncertainty. Announced in November 2025, the plan involves reducing Siemens AG's stake from 67% to about 37% by distributing 30% of Healthineers shares directly to its own shareholders. The lack of concrete details on the structure and timing of this complex spin-off is a latent overhang on the stock.

A bright spot comes from the U.S., where the company secured a ten-year partnership with provider Onvida Health worth over USD 100 million. This deal includes USD 55 million for new CT, MRI, and radiation therapy systems for a hospital in Arizona.

All eyes are now on the upcoming second-quarter report due on May 7. Analysts anticipate mid-to-high single-digit growth in the Imaging and Precision Therapy segments. However, the diagnostics division, facing ongoing China challenges and a tough prior-year comparison, is expected to remain the primary burden. The report will be a critical test of whether the company's confirmed full-year revenue growth target of 5 to 6% remains achievable.